Affordable Access

deepdyve-link
Publisher Website

[Secondary ITP in adults].

Authors
  • Michel, M1
  • Lega, J-C2
  • Terriou, L3
  • 1 Service de médecine interne, centre de référence pour les cytopénies auto-immunes de l'adulte, CHU Henri-Mondor, université Paris Est Créteil, Assistance publique-Hôpitaux de Paris, Créteil, France. Electronic address: [email protected] , (France)
  • 2 Service de médecine interne et vasculaire, centre de compétences cytopénies auto-immunes, hôpital Lyon Sud, Lyon, France. , (France)
  • 3 Département de médecine interne et immunologie clinique, CHU de Lille, Lille, France. , (France)
Type
Published Article
Journal
La Revue de medecine interne
Publication Date
Oct 31, 2020
Identifiers
DOI: 10.1016/j.revmed.2020.08.004
PMID: 33139079
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

Secondary forms of immune thrombocytopenia (ITP) represent approximately 20% of all ITP cases in adulthood and this rate increases with age. Since some causes may influence both the prognosis and outcome but also the management of ITP, a minimal workup must be performed at ITP diagnosis to look for an associated or underlying cause. Among adults, B-cell lymphomas and mainly chronic lymphocytic leukemia, systemic auto-immune diseases such as systemic lupus or primary immunodeficiencies mainly represented by common variable immunodeficiency are the most frequent causes of secondary ITP. Whereas first-line therapy used for secondary ITP is usually similar to the one commonly used in primary ITP and relies mostly on corticosteroids±intravenous immunoglobulin according to the severity of bleeding, second and third-line treatments must take into account the type and degree of activity of the underlying disease. Copyright © 2020 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times